Importantly, even though targeted treatments by use of BRAF/MEK inhibitors are known to lead to fast tumor responses in highly advanced patients with BRAF-V600-mutated melanoma, patients with normal LDH still achieve the better clinical outcome from treatment (74). Here, BRAF is linked to neoplasm.